Fig. 3
From: BIRC5 expression by race, age and clinical factors in breast cancer patients
Five-year recurrence-free survival (RFS) by BIRC5 expression status in CBCS. Kaplan–Meier survival analysis illustrating 5 year RFS in (A) all CBCS phase 3 cases, (B) among ER-positive/Her2-negative tumors only and (C) among triple-negative tumors only. Cox proportional hazard ratios and 95% confidence intervals adjusted for patient age and tumor stage are displayed within each plot for BIRC5-high relative to BIRC5-low tumors. All analyses were restricted to stage I-III tumors. Tick marks represent censored individuals. Shaded regions represent 95% confidence intervals for each group. ER: estrogen receptor; TNBC: triple-negative breast cancer; HR: hazard ratio; 95% CI: 95% Confidence Interval. Referent group = BIRC5-low for CoxPH models.